NASDAQ : MDGL

Madrigal Pharmaceuticals, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 431.7 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 9.97B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Details

NameMadrigal Pharmaceuticals, Inc.
SectorHealthcare
IndustryBiotechnology
Employees915
Founded2011
CeoWilliam Sibold
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS5588681057
Cusip558868105
Cik0001157601
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
William J. SiboldChief Executive Officer, President and Director
Dr. Rebecca A. Taub M.D.Founder, Senior Scientific and Medical Advisor and Director
Mardi C. DierExecutive Vice President and Chief Financial Officer
Shannon KelleyExecutive Vice President, Chief Legal Officer and Corporate Secretary
Carole HuntsmanExecutive Vice President and Chief Commercial Officer
Dr. David Soergel M.D.Executive Vice President and Chief Medical Officer
Mark UnderwoodExecutive Vice President of Business Planning and Operations
Rita ThakkarSenior Vice President and Chief Accounting Officer
Ronald FilippoExecutive Vice President and Chief Information Officer
Tina E. VenturaChief Investor Relations Officer

Contact

Address1001 Conshohocken State Road, Suite 2-350, West Conshohocken, Pennsylvania 19428, United States
Phone267 824 2827
Websitehttps://www.madrigalpharma.com